Is Bristol Myers Squibb One of the Best Dividend Stocks to Invest in According to Hedge Funds?
Bristol Myers Squibb has long been a stalwart of the pharmaceutical industry, but its recent announcement to deploy artificial intelligence across all aspects of its operations marks a significant shift in its approach.
The partnership with Anthropic to leverage Claude and Claude Code is more than just a nod to the trendiness of AI – it's an acknowledgment that this technology holds the key to unlocking unprecedented innovation and efficiency in the biopharmaceutical space.